Comparison of the effects of fenofibrate and polyene phosphatidylcholine in the treatment of non-alcoholic fatty liver disease

( views:60, downloads:0 )
Author:
HUANG Ke-qing(Department of Pharmacy , The First Hospital Affiliated to Medical College of Shantou University, Shantou , Guangdong 515041, China)
ZHENG Xiao-hui(Department of Pharmacy , The First Hospital Affiliated to Medical College of Shantou University, Shantou , Guangdong 515041, China)
WANG Guang-li(Department of Pharmacy , The First Hospital Affiliated to Medical College of Shantou University, Shantou , Guangdong 515041, China)
ZHUANG Jian-qi(Department of Pharmacy , The First Hospital Affiliated to Medical College of Shantou University, Shantou , Guangdong 515041, China)
Journal Title:
Chinese Journal of Primary Medicine and Pharmacy
Issue:
Volume 19, Issue 03, 2012
DOI:
10.3760/cma.j.issn.1008-6706.2012.03.003
Key Word:
Fenofibrate;Non-alcoholic fatty liver

Abstract: Objective To investigate the clinical effects of fenofibrate and polyene phosphatidylcholine in treatment of non-alcoholic fatty liver disease.Methods 86 patients with non-alcoholic fatty liver disease were randomly divided into two groups.45 cases in therapy group received 0.2g of fenofibrate once a day,and the others in control group received 456mg of polyene phosphatidylcholine for three times per day.All of the patients were treated for 12 weeks.Liver function,blood fat,clinical effect and liver B ultrasonic were analyzed before treatment and after 12 weeks.Results The improvement of liver function,blood fat,and liver ultrasonic imaging in therapy group was better than that in the control group.The cure rate was 82.2% in therapy group and 63.4% in control group.There was a statistical significance between the two groups ( x2 =3.874,P < 0.05).Conclusion Fenofibrate had significant therapeutic effect in treatment of non-alcoholic fatty liver disease with lower costs and lower side effects.

  • [1]余海峰,施慧飞.代谢综合征与脂肪肝的关系.中国医师杂志,2005,7(2):197.
  • [2]张艳君,文东,贾辉.非酒精性脂肪肝和代谢综合征的流行情况分析.中国基层医药,2010,17(9):1251-1252.
  • [3]翟木绪,李艳玲,陈慧,等.山东省日照市企事业单位职工非酒精性脂肪肝及其危险因素的流行病学调查.中国基层医药,2010,17(15):2077-2079.
  • [4]徐海峰,王永兵.江苏省南通市区体检人群脂肪肝的发病率和危险因素分析.中国基层医药,2010,17(24):3388-3390.
  • [5]Salgado Júnior W,Santos JS,Sankarankutty AK,et al.Nonalcoholic fatty liver disease and obesity.Acta Cir Bras,2006,21 (Suppl 1):72-78.
  • [6]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2006年2月修订).肝脏,2006,11(1):68-70.
  • [7]赵思文,冯婥.非酒精性脂肪肝与代谢综合征的关系.广东医学,2011,32(5):598-599.
  • [8]顾玉红,蓝玉进,杜佳新.非诺贝特致不良反应42例文献分析.中国药房,2010,21(40):3825-3826.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn